- ￥1700 - 4000
- GeneTex
- 美国
- GTX135356
- 2025年07月16日
- WB, ICC/IF, IHC-P, FACS, ELISA, Sandwich ELISA, IHC-P (cell pellet)
- Rabbit
- SARS Coronavirus 2
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant protein encompassing a sequence within the N-terminus region of SARS-CoV-2 (COVID-19) spike (S1) (SARS-CoV-2 (strain Wuhan-Hu-1)). The exact sequence is proprietary.
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
- 克隆性：
Polyclonal
- 标记物：
Unconjugated
- 适应物种：
SARS Coronavirus 2
- 保质期：
12 months from the shipping date of the product.
- 抗原来源：
SARS Coronavirus 2
- 目录编号：
GTX135356
- 级别：
Primary Antibodies
- 库存：
Available
- 供应商：
GeneTex
- 宿主：
Rabbit
- 应用范围：
WB, ICC/IF, IHC-P, FACS, ELISA, Sandwich ELISA, IHC-P (cell pellet)
- 浓度：
0.2 mg/ml (Please refer to the vial label for the specific concentration.)
- 靶点：
This antibody detects SARS-CoV-2 spike protein (S1 subunit), but does not cross-react with SARS-CoV or MERS-CoV spike proteins based on our internal testing.
- 抗体英文名：
SARS-CoV-2 (COVID-19) Spike antibody
- 抗体名：
SARS-CoV-2 (COVID-19) Spike 抗体
- 规格：
100 μl/25 μl
| 规格： | 100 μl | 产品价格： | ￥4000.0 |
|---|---|---|---|
| 规格： | 25 μl | 产品价格： | ￥1700.0 |
Indirect ELISA analysis was performed by coating plate with 50 μL of recombinant full-length SARS-CoV-2 (COVID-19) spike protein at concentrations ranging from 0.0625 μg/mL to 4 μg/mL. The coated protein is detected with SARS-CoV-2 (COVID-19) spike antibody (GTX135356) at 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.
Indirect ELISA analysis was performed by coating plate with 50 μL of recombinant SARS-CoV-2 (COVID-19) spike S1 subunit protein at concentrations ranging from 0.0625 μg/mL to 4 μg/mL. The coated protein is detected with SARS-CoV-2 (COVID-19) spike antibody (GTX135356) at 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.
Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 5% SDS-PAGE, and the membrane was blotted with SARS-CoV-2 (COVID-19) spike antibody (GTX135356) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
Sandwich ELISA detection of non-transfected (GTX535673) and SARS-CoV-2 spike (full length) transfected (GTX535664) 293T whole cell extracts using GTX632604 as capture antibody at concentration of 5 μg/mL and GTX135356 as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.
SARS-CoV-2 (COVID-19) spike antibody detects SARS-CoV-2 (COVID-19) spike protein by immunohistochemical analysis.
Sample: Paraffin-embedded SARS-CoV-2 (COVID-19) Spike FFPE Cell Pellet Block.
Green: SARS-CoV-2 (COVID-19) spike stained by SARS-CoV-2 (COVID-19) spike antibody (GTX135356) diluted at 1:1000.
Red: SARS-CoV / SARS-CoV-2 (COVID-19) spike stained by SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min
Non-transfected (–) and transfected (+) Vero E6 whole cell extracts (30 μg) were separated by 5% SDS-PAGE, and the membrane was blotted with SARS-CoV-2 (COVID-19) Spike antibody (GTX135356) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 5% SDS-PAGE, and the membrane was blotted with SARS-CoV-2 (COVID-19) spike antibody (GTX135356) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.
SARS-CoV-2 (COVID-19) Spike antibody detects SARS-CoV-2 (COVID-19) Spike protein by immunofluorescent analysis.
Sample: Mock and transfected 293T cells were fixed in 4% PFA at RT for 15 min.
Green: SARS-CoV-2 (COVID-19) Spike stained by SARS-CoV-2 (COVID-19) Spike antibody (GTX135356) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Merino VF et al., Antiviral Res 2023 (PMID:36740097)
Imanishi I et al., BMC Vet Res 2022 (PMID:36539820)
Park H et al., Adv Sci (Weinh) 2022 (PMID:35748162)
Ishigaki H et al., Front Microbiol 2022 (PMID:36466631)
Gellenoncourt S et al., J Virol 2022 (PMID:36121299)
Weijie Zeng et al., Front Cell Infect Microbiol 2022 (PMID:35755832)
Viviana V?squez et al., Anal Chim Acta 2022 (PMID:35414393)
Nanda Kishore Routhu et al., Immunity 2021 (PMID:33631118)
Miao-Hsi Hsieh et al., Front Immunol 2021 (PMID:34054808)
Lin WS et al., Front Immunol 2021 (PMID:34925381)
Meseda CA et al., NPJ Vaccines 2021 (PMID:34862398)
Ordonez AA et al., Commun Biol 2022 (PMID:35304580)
Yang B et al., Proc Natl Acad Sci U S A 2022 (PMID:35022217)
Huang HC et al., EBioMedicine 2021 (PMID:34839261)
Sci Immunol 2021;6(59)
Sukhikh G et al., Viruses 2021 (PMID:33801923)
Harbour JC et al., J Immunol 2021 (PMID:33972374)
Garc?a-Arriaza J et al., J Virol 2021 (PMID:33414159)
Sukhikh G et al., Viruses 2021;13(3)
SB Park et al., Commun Biol 2023 (PMID:37225764)
MJ Ruiz et al., Front Immunol 2022 (PMID:36248831)
Hayashi H et al., Sci Rep 2022 (PMID:36463322)
Prout A et al., Vaccine 2022 (PMID:35985887)
Gao SY et al., Front Immunol 2022 (PMID:36818474)
Arai Y et al., iScience 2023 (PMID:36507221)
Ruiz MJ et al., Front Immunol 2022 (PMID:36248831)
Kumar CS et al., ACS Infect Dis 2022 (PMID:36129193)
Vakhrusheva AV et al., Vaccines (Basel) 2022 (PMID:36016181)
MACSQuant Tyto 细胞分选仪助力开发 COVID-19 新疗法
丹麦奥胡斯大学医院传染病研究部门，Dr. Mariane H. Schleimann 与其团队现在正大量参与对新型冠状病毒(SARS-CoV-2)的研究。正如全世界的情况一样，迫切需要找到针对 COVID-19 有效的疫苗，以及治疗方法，这激发了许多基础研究、转化和临床组织共同投入到 COVID-19 研究中。 以下是由美天旎生物技术与 Dr. Mariane H. Schleimann 根据其对 COVID-19 研究进行的访谈: 1. Dr. Mariane H
COVID-19 infection. Nature Scientifc Reports 2:MacMullan,MA et al. (2020) ELISA detection of SARS-CoV-2 antibodies in saliva. Nature Scientifc Reports 3:Hettegger,P et al. (2019) High similarity of IgG antibody profles in blood and saliva opens
高福院士团队 Lancet 发文：北京 COVID-19 病例分析表明，疫情爆发期间未出现新变种
城到动态清零政策，精准防控，阻止了新冠病毒的传播。随着 Omicron 亚变体致病性的减弱、疫苗接种的普及和防控经验的积累，2022 年 11 月中旬，中国调整和优化了预防和控制策略。 中国在调整防控政策后，疫情在中国的快速传播引起了世界的关注，并引发了人们对此次疫情是否会驱动新 SARS-CoV-2 变体出现的担忧。因此，对流行的 SARS-CoV-2 变体进行全面的时空研究，对于全球应对当前的 COVID-19 大流行至关重要。北京拥有常住人口 2100 万，在政策调整后初期成为中国病例
技术资料暂无技术资料 索取技术资料
